Enanta Pharmaceuticals | ENTA - Уставный капитал обыкновенных акций





Уставный капитал обыкновенных акций Изменить Дата
AbbVie USD 1.77B 1.75B 2025-06
Amgen USD 540M 1000K 2026-03
Anika Therapeutics USD 13.89M 532K 2025-12
Arrowhead Research USD 135.7M 2.44M 2025-09
AstraZeneca USD 1.55B 73K 2026-03
BioCryst Pharmaceuticals USD 213.06M 2.54M 2025-12
Biogen USD 146.7M 200K 2025-09
Bristol-Myers Squibb USD 2.04B 1.74B 2025-09
Enanta Pharmaceuticals USD 212K 1000 2023-12
Gilead Sciences USD 1.24B 1000K 2025-12
GlaxoSmithKline GBP 4.05B 20.6M 2026-03
Halozyme Therapeutics USD 117.78M 259K 2025-12
Heron Therapeutics USD 188.31M 4.99M 2025-12
Immunic USD 120.38M 21.73M 2025-12
Incyte USD 199.95M 1.49M 2026-03
Insmed USD 214.26M 1.67M 2025-12
Ionis Pharmaceuticals USD 165.9M 3.93M 2026-03
J&J USD 2.41B 1.74M 2025-12
Karyopharm Therapeutics USD 18.31M 18.3M 2025-12
Ligand Pharmaceuticals USD 19.66M 19.64M 2025-09
Merck USD 2.47B 12.72M 2025-12
Neurocrine Biosciences USD 100.1M 400K 2025-12
Novartis USD 1.91B 60K 2026-03
Novavax USD 162.58M 106K 2025-12
Pfizer USD 5.69B 0 2025-12
PTC Therapeutics USD 81.47M 1.54M 2025-12
Roche Holding CHF 795.62M 699.54K 2025-12
Sarepta Therapeutics USD 104.96M 196K 2025-12
Vertex Pharmaceuticals USD 254.2M 200K 2026-03